^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Castration-Resistant Prostate Cancer

    Associations

    News

    Trials
    10h
    Antitumor Activity of Selenopsammaplin A Analog (SPA-10091-HCl) via Histone Methyltransferase DOT1L Degradation and Apoptosis Induction in Castration-Resistant Prostate Cancer Cells. (PubMed, Eur J Pharm Sci)
    Moreover, SPA-10091-HCl effectively inhibited tumor growth in the PC3 cells-implanted xenograft mouse model without any overt toxicity. These results indicate SPA-10091-HCl as a potential candidate for further development as a chemotherapeutic agent against CRPC.
    Journal • PARP Biomarker • IO biomarker • Epigenetic controller
    |
    BCL2 (B-cell CLL/lymphoma 2) • CDH1 (Cadherin 1) • CASP3 (Caspase 3) • VIM (Vimentin) • CASP9 (Caspase 9) • CDH2 (Cadherin 2) • DOT1L (DOT1 Like Histone Lysine Methyltransferase)
    |
    CDH1 expression • VIM expression
    10h
    FOG-001-101: FOG-001 in Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=480, Recruiting, Parabilis Medicines, Inc. | N=245 --> 480
    Enrollment change • Metastases
    |
    MSI (Microsatellite instability) • CTNNB1 (Catenin (cadherin-associated protein), beta 1)
    |
    Opdivo (nivolumab) • Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • Lonsurf (trifluridine/tipiracil) • leucovorin calcium • FOG-001
    10h
    Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=44, Not yet recruiting, Case Comprehensive Cancer Center
    New P2 trial • Metastases
    |
    carboplatin • cabazitaxel • Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    11h
    Mitochondrial unfolded protein response-dependent β-catenin signaling promotes neuroendocrine prostate cancer. (PubMed, Oncogene)
    Mitochondrial biogenesis facilitated cisplatin resistance and inhibition of UPRmt resensitizes CRPC-NE cells to cisplatin. Together, our findings demonstrated that UPRmt promotes mitochondrial health via upregulating β-catenin signaling and UPRmt represents viable therapeutic target for NEPC.
    Journal
    |
    HSPD1 (Heat Shock Protein Family D (Hsp60) Member 1)
    |
    cisplatin
    14h
    Castration-resistant prostate cancer is resensitized to androgen deprivation by autophagy-dependent apoptosis induced by blocking SKP2. (PubMed, Sci Signal)
    These effects were further enhanced by coinhibition of AR and were not induced by the AR inhibitor alone. Our findings indicate that targeting both AR and SKP2 signaling pathways is necessary to treat CRPC.
    Journal
    |
    TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • AR (Androgen receptor) • SKP2 (S-phase kinase-associated protein 2)
    1d
    Human Cytochrome P450 Cancer-Related Metabolic Activities and Gene Polymorphisms: A Review. (PubMed, Cells)
    The metabolic diversity and dual character of biological effects of CYPs underlie their implications in, preliminarily, hormone-sensitive cancers. Variations in CYP activities and CYP gene polymorphisms are implicated in the interindividual variability in cancer and drug susceptibility. The development of CYP inhibitors provides options for personalized anticancer therapy.
    Review • Journal
    |
    AR (Androgen receptor) • CYP17A1 (Cytochrome P450 Family 17 Subfamily A Member 1) • CYP1A2 (Cytochrome P450, family 1, subfamily A, polypeptide 2) • CYP2C8 (Cytochrome P450 Family 2 Subfamily C Member 8) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4) • CYP1A1 (Cytochrome P450 Family 1 Subfamily A Member 1) • CYP1B1 (Cytochrome P450 Family 1 Subfamily B Member 1)
    1d
    Roles of CDK12 mutations in PCa development and treatment. (PubMed, Biochim Biophys Acta Rev Cancer)
    Due to the poor prognosis of CDK12-mutant PCa patients and the mediocre response to classic standard therapies, HRD and increased neoantigen levels have provided clinicians with new insights into alternative systematic treatments for this novel PCa phenotype. In this review, we summarize the roles of CDK12 mutations in PCa and discuss their clinical value, suggesting that CDK12 potentially represents a target for further research and the development of clinical strategies for PCa.
    Review • Journal
    |
    AR (Androgen receptor) • HRD (Homologous Recombination Deficiency) • CDK12 (Cyclin dependent kinase 12)
    |
    HRD • CDK12 mutation • MYC expression
    2d
    Epigenetic remodeling and 3D chromatin reorganization governed by NKX2-1 drive neuroendocrine prostate cancer. (PubMed, bioRxiv)
    Lastly, NKX2-1/FOXA2 interacts with, and recruits CBP/p300 proteins to activate NE enhancers, and pharmacological inhibitors of CBP/p300 effectively blunted NE gene expression and abolished NEPC tumor growth. Thus, our study reports a hierarchical network of TFs governed by NKX2-1 in regulating the 2D and 3D chromatin re-organization during NET and uncovers a promising therapeutic approach to eradicate NEPC.
    Journal
    |
    FOXA2 (Forkhead Box A2)
    |
    NKX2-1 expression
    2d
    Validation and Performance of Quantitative BRCA1 and RAD51C Promoter Hypermethylation Testing in Breast and Ovarian Cancers. (PubMed, J Mol Diagn)
    The results demonstrate that this test can accurately quantitate the level of promoter methylation at the BRCA1 and RAD51C genes using FFPE samples, even when the extracted DNA is extremely degraded or the input amount is limited. This test increases the precision of diagnostic tests aimed at identifying patients who are likely and unlikely to respond to PARP inhibitor therapy.
    Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • HRD (Homologous Recombination Deficiency) • RAD51C (RAD51 paralog C)
    3d
    KEYNOTE-D13: A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors (clinicaltrials.gov)
    P2, N=166, Terminated, SOTIO Biotech AG | Active, not recruiting --> Terminated; Due to lack of expected efficacy shown at the time of the interim analysis
    Trial termination • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • nanrilkefusp alfa (SOT101)
    5d
    Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader. (PubMed, Mol Cancer Ther)
    Androgen receptor (AR) signaling is the principal driver of prostate cancer, and drugs that target this pathway (e.g., abiraterone and enzalutamide) are standard treatments for metastatic hormone-sensitive prostate cancer and metastatic castration-resistant prostate cancer (mCRPC). These promising preclinical data supported clinical development of bavdegalutamide as a potential treatment for patients with prostate cancer. Bavdegalutamide was the first PROTAC protein degrader to enter human clinical trials, specifically in patients with mCRPC in a phase 1/2 study (NCT03888612).
    Preclinical • Journal
    |
    AR (Androgen receptor) • CRBN (Cereblon)
    |
    AR expression
    |
    Xtandi (enzalutamide) • abiraterone acetate • bavdegalutamide (ARV-110)
    5d
    Antibody‑drug conjugates in prostate cancer: Emerging strategies to enhance therapeutic index and current clinical landscape (Review). (PubMed, Oncol Rep)
    In the present review, the developmental course, composition and mechanism of action of ADCs are explored, with a specific focus on recently published studies and ongoing trials aimed at investigating the efficacy and safety of ADCs in treating PCa. Lastly, ongoing challenges in ADC development and corresponding strategies to combat them are discussed.
    Review • Journal
    |
    CD276 (CD276 Molecule) • DLL3 (Delta Like Canonical Notch Ligand 3) • STEAP1 (STEAP Family Member 1) • CD46 (CD46 Molecule)
    5d
    A Study to Learn About the Safety of TALZENNA in People With Prostate Cancer. (clinicaltrials.gov)
    P=N/A, N=104, Not yet recruiting, Pfizer
    New trial • Metastases
    |
    BRCA (Breast cancer early onset)
    |
    Talzenna (talazoparib)
    5d
    PRL-02-1001: A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer (clinicaltrials.gov)
    P1, N=174, Recruiting, Astellas Pharma Global Development, Inc. | Trial completion date: Apr 2025 --> May 2029 | Trial primary completion date: Dec 2024 --> Aug 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    Xtandi (enzalutamide) • abiraterone acetate • prednisone • abiraterone decanoate (ASP5541)
    6d
    PRO-XL: XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=32, Recruiting, University of Utah | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    zanzalintinib (XL092)
    6d
    Post Marketing Study on Pluvicto in Korea (clinicaltrials.gov)
    P=N/A, N=278, Not yet recruiting, Novartis Pharmaceuticals | Trial completion date: Jul 2027 --> Mar 2029 | Initiation date: Oct 2024 --> May 2025 | Trial primary completion date: Jul 2027 --> Mar 2029
    Trial completion date • Trial initiation date • Trial primary completion date • Real-world evidence • Real-world
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    6d
    A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Men With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
    P1, N=232, Recruiting, Bayer | N=140 --> 232
    Enrollment change • Metastases
    |
    FOLH1 positive
    7d
    AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patients. (PubMed, Nat Commun)
    We develop a custom targeted cfDNA sequencing assay, named AR-ctDETECT, to detect ctDNA in limiting plasma cfDNA available from mCRPC patients in the Alliance A031201 randomized phase 3 trial of enzalutamide with or without abiraterone. ctDNA-positive patients have significantly worse median overall survival than ctDNA-negative patients (29.0 months vs. 47.4 months, respectively). Here, we show that mCRPC patients identified as ctDNA-positive using the AR-ctDETECT assay have poor survival despite treatment with potent AR inhibitors in a phase 3 trial.
    Clinical • Journal • Circulating tumor DNA • Metastases
    |
    MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
    |
    Xtandi (enzalutamide) • abiraterone acetate
    7d
    A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study (clinicaltrials.gov)
    P1, N=106, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    8d
    Castrate-resistant prostate cancer response to taxane is determined by an HNF1-dependent apoptosis resistance circuit. (PubMed, Cell Rep Med)
    Monotherapy with cIAP2 inhibitor LCL161 is sufficient to treat HNF1A+ models of mCRPC previously resistant to docetaxel. These data may be useful in future clinical trial designs.
    Journal
    |
    BIRC3 (Baculoviral IAP repeat containing 3) • HNF1A (HNF1 Homeobox A)
    |
    docetaxel • LCL161
    9d
    Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations (clinicaltrials.gov)
    P2, N=36, Recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2026
    Trial completion date • Trial primary completion date • Metastases
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • ARID1A (AT-rich interaction domain 1A) • BAP1 (BRCA1 Associated Protein 1) • CDK12 (Cyclin dependent kinase 12) • CHEK2 (Checkpoint kinase 2) • RAD51 (RAD51 Homolog A) • FANCA (FA Complementation Group A) • RAD51B (RAD51 Paralog B) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD50 (RAD50 Double Strand Break Repair Protein) • RAD51D (RAD51 paralog D) • CHEK1 (Checkpoint kinase 1) • BARD1 (BRCA1 Associated RING Domain 1) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • RAD54L (DNA Repair And Recombination Protein RAD54) • FANCF (FA complementation group F) • FANCL (FA Complementation Group L) • FANCI (FA Complementation Group I) • FANCM (FA Complementation Group M) • BACH1 (BTB Domain And CNC Homolog 1) • FANCD2 (FA Complementation Group D2) • FANCE (FA Complementation Group E) • FANCG (FA Complementation Group G) • FANCB (FA Complementation Group B) • FANCC (FA Complementation Group C)
    |
    BRCA2 mutation • BRCA1 mutation • ATM mutation
    |
    Talzenna (talazoparib)
    9d
    DKTK_PMO_1605: The Bispecific PSMAxCD3 Antibody CC-1 in Patients with Castration Resistant Prostate Carcinoma (clinicaltrials.gov)
    P1, N=86, Recruiting, University Hospital Tuebingen | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    CC-1
    9d
    CELLO-1: A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer (clinicaltrials.gov)
    P1/2, N=102, Terminated, Epizyme, Inc. | Active, not recruiting --> Terminated; Sponsor decision, no safety concern
    Trial termination • Combination therapy • Metastases
    |
    EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit)
    |
    Xtandi (enzalutamide) • abiraterone acetate • prednisone • Tazverik (tazemetostat)
    11d
    Talazoparib plus enzalutamide versus olaparib plus abiraterone acetate and niraparib plus abiraterone acetate for metastatic castration-resistant prostate cancer: a matching-adjusted indirect comparison. (PubMed, Prostate Cancer Prostatic Dis)
    Results suggest that TALA + ENZA may provide improvements in clinical outcomes relative to OLAP + AAP and NIRA + AAP in 1 L mCRPC; however, inherent limitations associated with the complexity of the analyses must be considered.
    Journal • PARP Biomarker • Metastases
    |
    HRD (Homologous Recombination Deficiency)
    |
    Lynparza (olaparib) • Talzenna (talazoparib) • Zejula (niraparib) • Xtandi (enzalutamide) • abiraterone acetate
    12d
    Cancer-Control Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer With BRCA Gene or Tumor Suppressor Mutations Undergoing 177-Lutetium Prostate-Specific Membrane Antigen Radioligand Therapy. (PubMed, JCO Precis Oncol)
    In real-world setting, substantially lower OS in mCRPC is observed for BRCA- and PTEN/TP53/RB1-mutated patients, whereas no difference in first-line PFS could be computed. In Lu-PSMA-treated patients, worst outcomes were observed for BRCA patients.
    Journal • BRCA Biomarker • Metastases
    |
    TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1) • BRCA (Breast cancer early onset)
    |
    TP53 mutation • PTEN mutation • RB1 mutation • BRCA mutation
    12d
    A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC (clinicaltrials.gov)
    P2, N=60, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Oct 2026 --> Aug 2025 | Trial primary completion date: Jan 2026 --> Dec 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    12d
    A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy (clinicaltrials.gov)
    P1/2, N=73, Active, not recruiting, Cellbion Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    13d
    Evolution of myeloid-mediated immunotherapy resistance in prostate cancer. (PubMed, Nature)
    Consistent with preclinical results, inhibition of A2ARs using ciforadenant in combination with programmed death 1 ligand 1 (PD-L1) blockade using atezolizumab induces clinical responses in patients with mCRPC. Moreover, inhibiting A2ARs results in a significant decrease in SPP1hi-TAM abundance in CRPC, indicating that this pathway is involved in both induction and downstream immunosuppression. Collectively, these findings establish SPP1hi-TAMs as key mediators of ICI resistance in mCRPC through adenosine signalling, emphasizing their importance as both a therapeutic target and a potential biomarker for predicting treatment efficacy.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • SPP1 (Secreted Phosphoprotein 1) • ADORA2A (Adenosine A2a Receptor)
    |
    Tecentriq (atezolizumab) • ciforadenant (CPI-444)
    13d
    CR108817: A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer (clinicaltrials.gov)
    P1, N=231, Recruiting, Janssen Research & Development, LLC | N=111 --> 231 | Trial primary completion date: Feb 2028 --> Sep 2027
    Enrollment change • Trial primary completion date • Metastases
    |
    JNJ-6420
    14d
    Management of Castration-Resistant Prostate Cancer with Oligometastases (clinicaltrials.gov)
    P2/3, N=102, Active, not recruiting, Sir Mortimer B. Davis - Jewish General Hospital | Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2025 --> Apr 2027
    Enrollment closed • Trial primary completion date
    |
    Xtandi (enzalutamide) • Eligard (leuprolide acetate) • triptorelin • goserelin acetate
    14d
    Comparative analysis of gut microbiota in hormone-sensitive and castration-resistant prostate cancer in Japanese men. (PubMed, Cancer Sci)
    These findings suggest that gut microbiota differences may be associated with prostate cancer progression. Further research is needed to explore the potential of targeting the microbiota as a therapeutic strategy.
    Journal
    |
    PTEN (Phosphatase and tensin homolog)
    15d
    A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC). (clinicaltrials.gov)
    P3, N=417, Recruiting, Hinova Pharmaceuticals Inc. | N=255 --> 417 | Trial primary completion date: Jun 2024 --> Dec 2024
    Enrollment change • Trial primary completion date • Metastases
    |
    docetaxel • abiraterone acetate • deutenzalutamide (HC-1119)
    15d
    NCI-2018-02052: PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer (clinicaltrials.gov)
    P=N/A, N=156, Active, not recruiting, University of California, San Francisco | Trial completion date: Jul 2025 --> Mar 2027 | Trial primary completion date: Jul 2025 --> Mar 2027
    Trial completion date • Trial primary completion date • Metastases
    17d
    COMRADE: Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis (clinicaltrials.gov)
    P1/2, N=133, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Nov 2024 --> Apr 2025 | Trial primary completion date: Nov 2024 --> Apr 2025
    Trial completion date • Trial primary completion date • Tumor mutational burden
    |
    HRD (Homologous Recombination Deficiency) • CD4 (CD4 Molecule)
    |
    HRD
    |
    OncoPanel™ Assay
    |
    Lynparza (olaparib) • Xofigo (radium Ra-223 dichloride)
    17d
    Testing BRCA 1-2 Mutations in Metastatic Prostate Cancer: Results of a Survey of the Italian Association of Medical Oncology. (PubMed, Clin Genitourin Cancer)
    BRCA testing in PC still presents several difficulties in clinical practice that can limit access to PARPi treatment. Better implementation of molecular testing to identify BRCA-mutated patients is crucial for tailored treatment in mCRPC.
    Journal • BRCA Biomarker • PARP Biomarker • Metastases
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation • BRCA mutation
    |
    Lynparza (olaparib)
    18d
    Integrative analysis identifies the atypical repressor E2F8 as a targetable transcriptional activator driving lethal prostate cancer. (PubMed, Oncogene)
    To target E2F8 in CRPC, we employed the CRISPR/CasRx system to knockdown E2F8 mRNA, resulting in effective and specific downregulation of E2F8 and its target oncogenes, as well as significant growth inhibition in AR-negative CRPC in both cultured cells and xenograft models. Our findings identify and characterize E2F8 as a targetable transcriptional activator driving CRPC, particularly the growth of AR-negative CRPC.
    Journal
    |
    AR (Androgen receptor) • E2F8 (E2F Transcription Factor 8)
    |
    AR positive
    20d
    APEX-01: ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer (clinicaltrials.gov)
    P1, N=352, Recruiting, Ambrx, Inc. | N=262 --> 352 | Trial completion date: Mar 2027 --> Dec 2028 | Trial primary completion date: Dec 2025 --> May 2026
    Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    FOLH1 (Folate hydrolase 1)
    |
    FOLH1 expression
    |
    abiraterone acetate • prednisone • Erleada (apalutamide) • JNJ-95298177
    20d
    Covalent adducts formed by the androgen receptor transactivation domain and small molecule drugs remain disordered. (PubMed, bioRxiv)
    Here, we utilize all-atom molecular dynamics computer simulations to simulate covalent adducts of the small molecule ligands EPI-002 and EPI-7170 bound to the disordered androgen receptor transactivation domain...We compare the populations of protein-ligand interactions observed in covalent adduct ensembles to those observed in non-covalent ligand-bound ensembles and find substantial differences. Our results provide atomically detailed descriptions of covalent adducts formed by small molecules and an intrinsically disordered protein and suggest strategies for developing more potent covalent inhibitors of intrinsically disordered proteins.
    Journal
    |
    AR (Androgen receptor)
    |
    EPI-7170
    20d
    PAF1-mediated transcriptional reprogramming confers docetaxel resistance in advanced prostate cancer. (PubMed, Cancer Lett)
    PAF1 depletion was also associated with decreased pluripotent TFs and other CSC markers. This study provides a novel regulatory mechanism of docetaxel resistance in PCa through PAF1 and establishes clinically relevant docetaxel-resistant PCa cell lines.
    Journal • Metastases
    |
    SOX2 • PAF1 (PAF1 Homolog, Paf1/RNA Polymerase II Complex Component)
    |
    docetaxel
    21d
    Theranostic Potential of the iPSMA-Bombesin Radioligand in Patients with Metastatic Prostate Cancer: A Pilot Study. (PubMed, Pharmaceutics)
    [99mTc]Tc-iPSMA-BN SPECT/CT is a promising alternative not only for diagnostic purposes but also for broadening the spectrum of PC patients who may benefit from radionuclide theranostics. The results justify the development of a clinical trial involving a significant number of patients with PC.
    Journal • Metastases
    |
    FOLH1 (Folate hydrolase 1)
    |
    FOLH1 expression
    21d
    Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=19, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Dec 2024 --> Jul 2025
    Trial completion date • Metastases
    |
    abiraterone acetate
    22d
    Extracellular vesicles derived-microRNAs predicting enzalutamide-resistance in 3D spheroid prostate Cancer model. (PubMed, Int J Biol Macromol)
    hsa-miR-221-3p and miR-222-3p were upregulated in all concentrations both intracellularly and in EVs. The developed 3D-spheroid model effectively replicated the ENZ resistance to ENZ in an AR-independent manner, underscoring the importance of EVs-derived miRNAs in this adaptive process.
    Preclinical • Journal
    |
    MIR221 (MicroRNA 221) • MIR22 (MicroRNA 22) • MIR222 (MicroRNA 222)
    |
    Xtandi (enzalutamide)